News
Staying the course would mean the Netherlands would lose out on around €70 million in R&D investments each year, said pharma association, VIG.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback